Program

What is our Symposium about

  • We promote interdisciplinary conversations and strengthen research network.
  • We identify new pathogenic targets, biomarkers, and intricate signallingpathways to provide a comprehensive perspective on disease pathogenesis.
  • We propose and pioneer new therapeutic strategies.

Preliminary Program

12:00 p.m. – 2:00 p.m. Welcome Address / Lunch + Poster I / Industry I
2:00 p.m. – 4:50 p.m. Session I: Autoimmune Disease and the Role of Autoantibodies
Chair: N.N.
2:00 p.m. – 2:10 p.m. Welcome
UzL Präsidium
2:10 p.m. – 2:40 p.m. Keynote: Concepts of autoimmunity
Prof. Dr. Y. Shoenfeld
2:40 p.m. – 3:00 p.m. GPCR abs Network in autoimmune and chronic inflammatory diseases
Prof. Dr. G. Riemekasten
3:00 p.m. – 3:20 p.m. Antibodies targeting GPCR in health and disease
Prof. Dr. O. Cabral-Marques (remote)
3:35 p.m. – 4:50 p.m. GPCR abs as biomarker in SSc
Dr. S. Schinke
4:50 p.m. – 5:10 p.m. Coffee Break
5:10 p.m. – 6:10 p.m. Session II: Autoantibody-Induced Disease Mechanisms
Chair: N.N.
5:10 p.m. – 5:25 p.m. GPCR abs as allosteric modulators, Vasculopathy
Dr. D. Veprintsev
5:25 p.m. – 5:40 p.m. GPCR-Directed Autoantibodies in Glomerular Diseases: Toward Novel Biomarkers and Precision Nephrology
Prof. Dr. M. Banasik
5:40 p.m. – 5:55 p.m. GPCR abs in early SSc
Dr. J. Ohmes
5:55 p.m. – 6:10 p.m. Abs-mediated angiotensin II type 1 receptor activation induces endothelial dysfunction in SSc
MD Cand. M. Jäpel / PD Dr. R. Akbarzadeh
9:00 a.m. – 11:00 a.m. Session III: Organ-Specific Autoantibody Pathology
Chair: N.N.
9:00 a.m. – 9:15 a.m. Pathogenic and regulatory autoantibodies in MS, NMOSD and MOGAD
Prof. Dr. F. Paul
9:15 a.m. – 9:30 a.m. Cardiovascular disease (CVD)
Prof. Dr. T. Zeller
9:30 a.m. – 9:45 a.m. Keratinocyte-targeting functional autoantibodies in systemic sclerosis are associated with interstitial lung disease
Prof. Dr. X. Yu / Dr. J. Wax
9:45 a.m. – 10:00 a.m. Complement 5a receptor-targeting antibodies and their relevance in vasculitis beyond AAV
Dr. S. Klapa
10:00 a.m. – 10:15 a.m. GPCR abs in transplantation
Dr. G. Moll
10:15 a.m. – 10:30 a.m. GPCR abs in RA
D. Oviedo
10:30 a.m. – 10:45 a.m. Abs-driven disease severity in PsA
MD Cand. L. Berg / Dr. H. Grasshoff
10:45 a.m. – 11:00 a.m. Coagulation beyond clotting: the clot thickens – regulation of organ function by coagulation protease signalling
Prof. Dr. B. Isermann
11:00 a.m. – 11:45 a.m. Extended Coffee Break, Industry II and Poster Session II
11:45 a.m. – 1:35 p.m. Session IV: Autoantibodies in Fatigue and Neurological Disorders
Chair: N.N.
11:45 a.m. – 12:05 p.m. ME/CFS – the role of autoimmunity and antibody-targeting therapies
Prof. Dr. C. Scheibenbogen
12:05 p.m. – 12:20 p.m. Specific Antibodies and Antigens in Post-COVID and ME/CFS
Dr. F. Sotzny
12:20 p.m. – 12:35 p.m. ME/CFS, a neurodegenerative autoimmune disease?
Dr. A. Hackel
12:35 p.m. – 12:50 p.m. STU Talk: From Autoantibodies to Gene Expression: IgG-Mediated Transcriptome Changes in ME/CFS
MSc. M. Mennenga / Dr. A. Hackel
12:50 p.m. – 1:05 p.m. The brain endothelial GPCR signaling as link between autoimmune diseases and cognitive impairment
PD Dr. J. Wenzel
1:05 p.m. – 1:20 p.m. STU Talk: Functional Autoantibody Alterations Across the Lifespan in ME/CFS
BSc. M. Vollert / Dr. A. Hackel
1:20 p.m. – 1:35 p.m. Expert panel: Clinical translation
1:35 p.m. – 2:45 p.m. Lunch, Poster Session III and Industry III
2:45 p.m. – 5:10 p.m. Session V: Precision Medicine & Diagnostics
Chair: N.N.
2:45 p.m. – 3:05 p.m. Keynote: Abs–GPCRs, Mechanism behind
Prof. Dr. T. Sakmar
3:05 p.m. – 3:20 p.m. C5aR1 abs in Chronic Inflammatory Diseases (CD)
Prof. Dr. L. Björkman
3:20 p.m. – 3:35 p.m. Gold-enabled high-resolution tracking of GPCR abs binding
MSc. Katja Werner
3:35 p.m. – 3:50 p.m. Combining Optical Technology with abs, SSc, PsA
Dr. H. Grasshoff
4:05 p.m. – 4:20 p.m. GPCR abs: Function is key
Dr. A. Hackel
4:20 p.m. – 4:40 p.m. Coffee Break
4:40 p.m. – 4:55 p.m. Distinct extracellular vesicle signatures association with GPCR abs in SSc
PhD Cand. P. Bonney
4:55 p.m. – 5:10 p.m. Functional Autoantibody Responses Identify Distinct ILD Patient Phenotypes
MD Cand. L. Schnoor / Dr. A. Hackel
5:10 p.m. – 5:25 p.m. Closing panel: Future directions
5:25 p.m. – 5:55 p.m. Farewell